Ivan Pinos, Amparo Blanco, Jennifer Kelschenbach, Mike Veenstra, Eva Hu, Hongxia He, Joan W Berman, David J Volsky, Jaume Amengual
{"title":"EcoHIV Infection Promotes Atherosclerosis Progression in LDLR-Deficient Mice.","authors":"Ivan Pinos, Amparo Blanco, Jennifer Kelschenbach, Mike Veenstra, Eva Hu, Hongxia He, Joan W Berman, David J Volsky, Jaume Amengual","doi":"10.1161/ATVBAHA.125.323004","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>People with HIV are at higher risk of atherosclerotic cardiovascular disease than uninfected individuals; however, the molecular mechanisms behind this association remain elusive due to the lack of suitable animal models.</p><p><strong>Methods: </strong>To study the impact of HIV on atherosclerotic cardiovascular disease, we infected the atheroprone <i>Ldlr</i><sup><i>-/-</i></sup> mice with the chimeric virus EcoHIV.</p><p><strong>Results: </strong>In comparison to uninfected controls, EcoHIV infection increased the ratio of circulating inflammatory monocytes, monocyte recruitment, and CD68<sup>+</sup> content in the atherosclerotic lesion. These changes occurred independently of alterations in plasma lipid profile or lesion size between groups. Lesions of EcoHIV-infected mice displayed greater vulnerability to rupture, as determined by increased necrotic core area and CD38<sup>+</sup> content, and reduced presence of collagen compared with uninfected mice. Last, we report the presence of active viral replication of EcoHIV in the atherosclerotic lesion.</p><p><strong>Conclusions: </strong>Our data suggest that EcoHIV infection in <i>Ldlr</i><sup><i>-/-</i></sup> mice resembles the pathogenesis of atherosclerotic cardiovascular disease in people with HIV. Our findings have therapeutic implications for people with HIV, a vulnerable population with an elevated risk of cardiovascular disease.</p>","PeriodicalId":8401,"journal":{"name":"Arteriosclerosis, Thrombosis, and Vascular Biology","volume":" ","pages":"e470-e482"},"PeriodicalIF":7.4000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arteriosclerosis, Thrombosis, and Vascular Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/ATVBAHA.125.323004","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/4 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: People with HIV are at higher risk of atherosclerotic cardiovascular disease than uninfected individuals; however, the molecular mechanisms behind this association remain elusive due to the lack of suitable animal models.
Methods: To study the impact of HIV on atherosclerotic cardiovascular disease, we infected the atheroprone Ldlr-/- mice with the chimeric virus EcoHIV.
Results: In comparison to uninfected controls, EcoHIV infection increased the ratio of circulating inflammatory monocytes, monocyte recruitment, and CD68+ content in the atherosclerotic lesion. These changes occurred independently of alterations in plasma lipid profile or lesion size between groups. Lesions of EcoHIV-infected mice displayed greater vulnerability to rupture, as determined by increased necrotic core area and CD38+ content, and reduced presence of collagen compared with uninfected mice. Last, we report the presence of active viral replication of EcoHIV in the atherosclerotic lesion.
Conclusions: Our data suggest that EcoHIV infection in Ldlr-/- mice resembles the pathogenesis of atherosclerotic cardiovascular disease in people with HIV. Our findings have therapeutic implications for people with HIV, a vulnerable population with an elevated risk of cardiovascular disease.
期刊介绍:
The journal "Arteriosclerosis, Thrombosis, and Vascular Biology" (ATVB) is a scientific publication that focuses on the fields of vascular biology, atherosclerosis, and thrombosis. It is a peer-reviewed journal that publishes original research articles, reviews, and other scholarly content related to these areas. The journal is published by the American Heart Association (AHA) and the American Stroke Association (ASA).
The journal was published bi-monthly until January 1992, after which it transitioned to a monthly publication schedule. The journal is aimed at a professional audience, including academic cardiologists, vascular biologists, physiologists, pharmacologists and hematologists.